Anti-EGFR therapy in the context of cancer treatment may have cardiotoxic side effects, maybe due to EC dysfunction, because EGFR, which is normally involved in EGF/neuregulin signaling, can also form a holoreceptor with NRP1 and elicits a repellent SEMA3D signal in venous ECs [187]. The gene discussed is EGF; the disease is cancer.